<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241631</url>
  </required_header>
  <id_info>
    <org_study_id>mitHDAC#1</org_study_id>
    <nct_id>NCT00241631</nct_id>
  </id_info>
  <brief_title>Enhancement of in−Vitro GC Function in Patients With COPD</brief_title>
  <official_title>Enhancement of In-vitro GC Function in Patients With COPD. A Randomised, Double Blind, Placebo Controlled, Parallel-group Study to Investigate the Effect of Theophylline and Fluticasone on Induced Sputum Cells Obtained Form COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator wish therefore to continue these studies on theophylline principally by
      conducting a small clinical pilot study on 20−30 COPD patients in a randomised, double−blind,
      placebo−controlled, parallel−group study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The global burden of COPD − a common and debilitating chronic inflammatory disease that is
      characterised by the progressive development of airflow limitation (shortness of breath −
      SOB) and is poorly reversible with currently available drugs −is increasing. Cigarette
      smoking is strongly linked with the ongoing inflammation; inflammation that can continue even
      when the patient has stopped smoking. The severity of airflow limitation (SOB) is correlated
      with the degree of pulmonary (lung) inflammation.

      Histone deacetylases (HDACs)are important molecules in suppressing this pulmonary
      inflammation. We have recently shown that patients with COPD have a reduction in total HDAC
      which correlates with the severity of their lung disease.

      Corticosteroids (anti−inflammatory treatment) act, at least in part, by recruitment of these
      HDACs to the site of active inflammatory gene transcription (which reduces the production of
      inflammatory molecules) and are widely used in COPD in patients with severe disease.
      Unfortunately, in COPD, inhaled corticosteroids seem to have little effect on the underlying
      inflammation (though in a selective group of patients with COPD they do reduce the number of
      infections a patient may have by a small amount).

      Theophylline has been used in the treatment of asthma and COPD for over 70 years, but its use
      has recently declined. Data so far obtained in primary cells (cells from patients used in the
      laboratory) from COPD patients suggests that low dose theophylline (~5mg/l) should be
      effective in restoring steroid sensitivity in patients with COPD (and hence reduce
      inflammation thus improving SOB).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum Inflammatory Cell Counts</measure>
    <time_frame>10 weeks</time_frame>
    <description>Supernatant collect, cell pellets count on slides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8 (IL8)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Interleukin 8 (IL8) assessed from sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sputum Eosinophils</measure>
    <time_frame>10 weeks</time_frame>
    <description>Total eosinophils cells assessed from sputum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Theophylline placebo capsule, then placebo, then active Theophylline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate</intervention_name>
    <description>500 u</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>Theophylline placebo capcule</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Participants with COPD with an FEV1 of 80−30% predicted. This will
        incorporate the majority of participants with COPD seen within the chest clinic. Patients
        with an FEV1 &gt; 80% predicted are not generally severe enough to warrant hospital follow up.
        These patients are also unlikely to have severe enough disease (and therefore airway
        inflammation) which may be modified by the therapeutic agents we are studying.

        Patients with an FEV1 &lt; 30% tend to have more severe symptom limitation and generally
        (though not always) find participation in a clinical trial involving 4 visits to the clinic
        difficult. Their airway disease is also generally less responsive to therapeutic
        intervention and as a consequence finding measurements which show changes to these
        therapeutic interventions is more difficult.

        COPD patients

          -  All participants will be classified to Stage 2−3 of the GOLD (Global initiative for
             Obstructive Lung Disease) guidelines

          -  Male or female, aged 45-80 years (according to GOLD guidelines)

          -  30% &lt; FEV1 &lt; 80% predicted

          -  FEV1/FVC &lt; 70%

          -  Cigarette exposure of &gt;10 pack−years#

          -  With or without chronic symptoms (cough, sputum production, dyspnea).

          -  Steroid therapy will be stopped before run−in, but long acting bronchodilators are
             acceptable.

          -  The participants are able to give informed consent # The smoking history should
             include both the number smoked, for how long, and an estimate of total pack−years of
             smoking. One pack of 20 cigarettes smoked per day for 1 year = one pack year. Total
             pack years = No. cigarettes smoked per day/20 x no. years of smoking

        Exclusion Criteria:

        Any history or evidence of asthma

          -  Pregnancy, breast−feeding or planned pregnancy during the study. Fertile women not
             using acceptable contraceptive measures, as judged by the investigator

          -  Hospital admission with respiratory infection within the last 6 months

          -  Upper respiratory infection within the last 4 weeks

          -  Participants who have received research medication within the previous one month

          -  Participants unable to give informed consent

          -  Any mental condition rendering the participant unable to understand the nature, scope
             and possible consequences of the study

          -  Known or suspected hypersensitivity to study therapy or excipients

          -  Participants with significant or unstable ischemic heart disease, arrhythmia,
             cardiomyopathy, heart failure, uncontrolled hypertension as defined by the
             investigator, or any other relevant cardiovascular disorder as judged by the
             investigator

          -  Any current respiratory tract disorders other than COPD, which is considered by the
             investigator to be clinically significant

          -  Any significant disease or disorder (e.g. gastrointestinal, liver, renal,
             neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major
             physical impairment) or abnormality laboratory tests which, in the opinion of the
             investigator, may either put the participant at risk because of inclusion in the
             study, or may influence the results of the study, or the participants ability to take
             part in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ian adcock, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Windsor chest clinic KEVII Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Berks</state>
        <zip>SL4 3DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005 May 12;352(19):1967-76.</citation>
    <PMID>15888697</PMID>
  </reference>
  <results_reference>
    <citation>Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010 Jun;137(6):1338-44. doi: 10.1378/chest.09-2363. Epub 2010 Mar 18.</citation>
    <PMID>20299628</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 18, 2005</study_first_submitted>
  <study_first_submitted_qc>October 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <results_first_submitted>August 21, 2019</results_first_submitted>
  <results_first_submitted_qc>November 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2019</results_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Inhaled Theophylline placebo capsule, then inhaled placebo, then active Theophylline</description>
        </group>
        <group group_id="P2">
          <title>Steroid</title>
          <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run in (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 1 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>sore throat</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Wash Out (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Inhaled Theophylline placebo capsule, then inhaled placebo, then active Theophylline</description>
        </group>
        <group group_id="B2">
          <title>Steroid</title>
          <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="2.2"/>
                    <measurement group_id="B2" value="69" spread="1.9"/>
                    <measurement group_id="B3" value="65" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum Inflammatory Cell Counts</title>
        <description>Supernatant collect, cell pellets count on slides</description>
        <time_frame>10 weeks</time_frame>
        <population>Using marginal means as results</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Theophylline placebo capsule, then inhaled placebo, then active Theophylline</description>
          </group>
          <group group_id="O2">
            <title>Steroid</title>
            <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Inflammatory Cell Counts</title>
          <description>Supernatant collect, cell pellets count on slides</description>
          <population>Using marginal means as results</population>
          <units>millions cells/ ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" lower_limit="3.56" upper_limit="8.2"/>
                    <measurement group_id="O2" value="3.89" lower_limit="2.6" upper_limit="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 8 (IL8)</title>
        <description>Interleukin 8 (IL8) assessed from sputum</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Theophylline placebo capsule, then inhaled placebo, then active Theophylline</description>
          </group>
          <group group_id="O2">
            <title>Steroid</title>
            <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 8 (IL8)</title>
          <description>Interleukin 8 (IL8) assessed from sputum</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20" upper_limit="56"/>
                    <measurement group_id="O2" value="28.3" lower_limit="19" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>calculated</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sputum Eosinophils</title>
        <description>Total eosinophils cells assessed from sputum</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Theophylline placebo capsule, then inhaled placebo, then active Theophylline</description>
          </group>
          <group group_id="O2">
            <title>Steroid</title>
            <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sputum Eosinophils</title>
          <description>Total eosinophils cells assessed from sputum</description>
          <units>millions cells/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" lower_limit="0.09" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.053" lower_limit="0.03" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>calculated</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Inhaled Theophylline placebo capsule, then inhaled placebo, then active Theophylline</description>
        </group>
        <group group_id="E2">
          <title>Steroid</title>
          <description>Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea and upset stomach</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ian M Adcock</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 7594 7840</phone>
      <email>ian.adcock@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

